FOXO4-DRI Certificate of Analysis (COA) Standards
A rigorous Certificate of Analysis (COA) is essential for validating the purity, molecular identity, and biological suitability of FOXO4-DRI in laboratory experimentation. This document provides an exhaustive technical overview of the analytical testing protocols used to verify lot-specific FOXO4-DRI, including HPLC, mass spectrometry, endotoxin quantification, and physical characterization.
Quick answer
A rigorous Certificate of Analysis (COA) is essential for validating the purity, molecular identity, and biological suitability of FOXO4-DRI in laboratory experimentation. This document provides an exhaustive technical overview of the analytical testing protocols used to verify lot-specific FOXO4-DRI, including HPLC, mass spectrometry, endotoxin quantification, and physical characterization.
Key takeaways
- FOXO4-DRI (FOXO4 D-Retro-Inverso) is a synthetic D-amino acid peptide designed to disrupt the interaction between the FOXO4 transcription factor and the p53 tumor suppressor protein.
- A compliant, audit-ready [Certificate of Analysis](/research-peptides/what-is-a-coa-for-peptides) must provide multi-modal analytical evidence generated by an independent, ISO 17025-accredited analytical testing facility.
- High-Performance Liquid Chromatography is the gold-standard method for determining the chemical purity of synthetic peptides.
- While HPLC evaluates chemical purity, it cannot definitively confirm molecular identity.
Introduction to FOXO4-DRI Analytical Standards
FOXO4-DRI (FOXO4 D-Retro-Inverso) is a synthetic D-amino acid peptide designed to disrupt the interaction between the FOXO4 transcription factor and the p53 tumor suppressor protein. In cell culture and animal models, this compound has been extensively studied for its ability to selectively induce apoptosis in senescent cells while leaving non-senescent somatic cells unharmed. Because FOXO4-DRI is a modified, multi-residue sequence containing D-enantiomeric amino acids, precise structural verification and chemical purity analysis are paramount before executing in vitro or preclinical experiments.
To ensure experimental reproducibility across molecular assays, researchers must rely on independent, third-party chemical validation. A comprehensive foxo4-dri coa serves as the primary instrument for verifying that a given lot meets strict analytical thresholds. Without verifiable analytical data, secondary metabolites, incomplete peptide synthesis fragments, or endotoxin contamination can confound experimental endpoints in cellular senescence research.
Key Components of a Legitimate FOXO4-DRI COA
A compliant, audit-ready Certificate of Analysis must provide multi-modal analytical evidence generated by an independent, ISO 17025-accredited analytical testing facility. A valid COA goes beyond simple statements of purity; it displays raw quantitative spectra, methodology, instrument calibration metrics, and lot-specific batch identification.
Primary parameters included on a legitimate FOXO4-DRI COA encompass high-performance liquid chromatography (HPLC) chromatograms, mass spectrometry (MS) mass-to-charge ($m/z$) ratio confirmation, bacterial endotoxin quantification, Karl Fischer titration for residual moisture content, and visual appearance specifications. These metrics collectively establish that the research material is structurally authentic and free of interfering synthesis reagents, organic solvents, or microbiological pyrogen load.
High-Performance Liquid Chromatography (HPLC) Purity Verification
High-Performance Liquid Chromatography is the gold-standard method for determining the chemical purity of synthetic peptides. Reverse-phase HPLC (RP-HPLC) separates the primary target sequence from closely related impurities, such as deletion sequences, oxidized species, or truncated peptide fragments resulting from incomplete coupling steps during solid-phase peptide synthesis (SPPS).
On a standard foxo4-dri coa, HPLC purity is expressed as a peak area percentage (Area %). A sharp, singular main peak indicates a highly homogenous compound. Reliable laboratory research standards require a minimum HPLC purity threshold of ≥98.0%. The chromatogram provided in the COA must display clear baseline resolution, retention time ($t_R$), and peak integration details to confirm that trace impurities fall below acceptable laboratory thresholds. Researchers evaluating analytical protocols can reference our guide on peptide purity testing via HPLC and MS to better interpret chromatographic resolution and column integration parameters.
Mass Spectrometry (MS) Sequence & Molecular Weight Confirmation
While HPLC evaluates chemical purity, it cannot definitively confirm molecular identity. Mass Spectrometry (MS)—typically utilizing Electrospray Ionization (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF)—is required to confirm the precise molecular weight of the FOXO4-DRI peptide chain.
The theoretical monoisotopic mass or average molecular weight of FOXO4-DRI is calculated based on its specific amino acid sequence and D-amino acid retro-inverso configuration. The MS spectrum on a certified COA displays observed mass-to-charge ratios ($m/z$), including multiply charged states ($[M+H]^+$, $[M+2H]^{2+}$, $[M+3H]^{3+}$). A match between the theoretical molecular weight and the observed spectrum confirms sequence integrity, verifying that no amino acid deletions, additions, or major side-chain modifications occurred during synthesis.
Endotoxin Quantification via LAL Assay
Bacterial endotoxins—primarily lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria—pose a significant risk in cell culture and preclinical research. Exposure to endotoxins in cell assays can trigger non-specific inflammatory signaling pathways, altering cytokine release, mitochondrial function, and gene expression independently of the target peptide's mechanism.
To ensure valid experimental outcomes, FOXO4-DRI lots undergo quantitative endotoxin testing using the Limulus Amebocyte Lysate (LAL) kinetic chromogenic assay. The standard specification for research-grade FOXO4-DRI requires an endotoxin level below 10 EU/mg, with premium analytical lots demonstrating levels far lower. Details regarding pyrogen quantification methods can be explored further in our overview of endotoxin testing in research peptides.
Physical Characterization: Appearance, Moisture, and Solubility
Physical quality indicators provide additional validation of structural stability and processing quality. Standard specifications listed on a legitimate COA include:
• Appearance: A lyophilized, uniform white-to-off-white powder, free of foreign particulate matter. • Moisture Content: Determined via Karl Fischer titration or thermogravimetric analysis (TGA). Excess residual moisture (>5%) can accelerate peptide hydrolysis, leading to chemical degradation during storage. • Counterion / TFA Content: Residual trifluoroacetic acid (TFA) salt content from purification phase, which should be quantified or controlled to maintain buffer pH integrity upon reconstitution. • Solubility Profile: Verification that the lyophilized cake reconstitutes rapidly and completely in standard laboratory vehicles such as sterile bacteriostatic water or phosphate-buffered saline (PBS).
FOXO4-DRI Mechanism & In Vitro Research Context
In preclinical studies, FOXO4-DRI has been investigated for its capacity to disrupt the FOXO4-p53 interaction complex. In senescent cells, FOXO4 binds to p53 and prevents it from initiating apoptosis, maintaining cellular senescence and the continuous secretion of senescence-associated secretory phenotype (SASP) factors. In vitro studies demonstrate that introducing FOXO4-DRI competes for the binding domain, displacing p53 and allowing it to initiate targeted apoptotic pathways specifically within senescent cell populations.
Because senescent cell signaling assays are sensitive to subtle changes in protein expression and receptor signaling, researchers must ensure their FOXO4-DRI test material is free of degraded peptide fragments that could falsely induce cytotoxic responses. Accessing fully documented material through the PX1 Research catalog guarantees high analytical fidelity for cellular aging and senolytic pathway studies.
Comparative Analytical Profile: FOXO4-DRI and Related Research Compounds
When designing protocols in cellular homeostasis, mitochondrial signaling, or metabolic pathways, laboratory researchers often compare FOXO4-DRI with other target peptides. Below is a comparative analytical breakdown of related research compounds available for laboratory investigation:
While FOXO4-DRI focuses on senolytic target interaction via D-amino acid retro-inverso structure, compounds like MOTS-c are evaluated for mitochondrial-derived metabolic regulation, and SS-31 (Elamipretide) targets mitochondrial cardiolipin stabilization to reduce reactive oxygen species (ROS). Comparative evaluation of these peptides requires verifying unique molecular weights and counterion balances on their respective lot COAs. Researchers conducting broad comparative studies can explore option packages via our wholesale lab accounts for bulk batch allocations.
Reconstitution, Storage, and Handling Guidelines for Laboratory Use
To preserve the analytical integrity confirmed on the COA, correct handling protocols must be maintained upon receipt. FOXO4-DRI is shipped as a freeze-dried (lyophilized) powder. Upon arrival, the desiccated vial should be stored in a dry environment at -20°C or -80°C to prevent hydrolysis.
When preparing solutions for in vitro assays or preclinical models, reconstitution should be performed under a laminar flow hood using sterile, degassed solvents such as sterile PBS or laboratory-grade reconstitution vehicles. Once reconstituted, single-use aliquots should be prepared immediately to avoid repeated freeze-thaw cycles, which cause peptide cleavage and aggregation. Aliquoted solutions stored at -80°C typically maintain chemical stability for up to 6 months, whereas working solutions kept at 4°C should be utilized within 24 to 48 hours.
PX1 Research Quality Assurance & Lot Traceability
PX1 Research maintains rigorous quality assurance standards for all USA-synthesized research peptides. Every batch of FOXO4-DRI undergoes rigorous third-party analytical testing prior to release. We make lot-specific Certificates of Analysis directly accessible to research staff to verify HPLC purity, mass spectra, and endotoxin assay results.
All PX1 Research products are manufactured in GMP-compliant facilities and tested in ISO 17025 accredited laboratories located in California and Arizona. Orders ship same-day (Monday through Friday), ensuring rapid transition from analytical synthesis to laboratory storage while maintaining thermal stability. Explore our comprehensive library of analytical data and peptide references in our research peptide database.
Frequently Asked Questions
Where can I view the lot-specific COA for my FOXO4-DRI shipment?
Lot-specific Certificates of Analysis for PX1 Research compounds are accessible directly on the product documentation portal or by scanning the lot tracking code on the product label.
What is the acceptable HPLC purity threshold for FOXO4-DRI in cell culture research?
PX1 Research requires a minimum HPLC purity threshold of ≥98.0% for FOXO4-DRI. High purity is critical in cellular senescence research to prevent non-specific cytotoxicity caused by peptide fragments.
How is the molecular identity of FOXO4-DRI confirmed on the COA?
Molecular identity is confirmed using Mass Spectrometry (ESI-MS or MALDI-TOF), which compares the observed mass-to-charge ($m/z$) ratios against the theoretical molecular weight of the retro-inverso peptide sequence.
What endotoxin limits apply to FOXO4-DRI for in vitro assays?
Research-grade FOXO4-DRI is tested via LAL chromogenic assay and must demonstrate endotoxin levels below 10 EU/mg, minimizing inflammatory background signals in sensitive cell culture models.
Why is moisture content testing important on a peptide COA?
Residual moisture in lyophilized peptides can initiate hydrolysis during storage, causing peptide bond degradation. Karl Fischer titration ensures moisture levels remain below 5% for optimal stability.
How should FOXO4-DRI be reconstituted for laboratory protocols?
Reconstitution should be conducted using sterile laboratory solvents such as phosphate-buffered saline (PBS) or sterile bacteriostatic water under sterile laminar flow conditions.
What is the primary mechanism of FOXO4-DRI investigated in preclinical models?
Preclinical studies suggest that FOXO4-DRI acts as a competitive antagonist that disrupts the FOXO4-p53 protein complex, allowing p53 to selectively trigger apoptosis in senescent cells.
Are PX1 Research compounds synthesized and tested in the United States?
Yes. All PX1 Research peptides are USA-synthesized and independently verified by accredited third-party laboratories to ensure full analytical compliance.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.